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Abstract
BACKGROUND: Peripheral blood lymphocytes of patients with hematological malignancies or solid tumors, such
as renal cell carcinoma or prostate cancer, display epigenetic aberrations (loss of synchronous replication of allelic
counterparts) and genetic changes (aneuploidy) characteristic of the cancerous phenotype. This study sought to
determine whether such alterations could differentiate breast cancer patients from cancer-free subjects.METHODS:
The HER2 locus—an oncogene assigned to chromosome 17 whose amplification is associated with breast cancer
(BCA)—and the pericentromeric satellite sequence of chromosome 17 (CEN17) were used for replication timing
assessments. Aneuploidy was monitored by enumerating the copy numbers of chromosome 17. Replication timing
and aneuploidy were detected cytogenetically using fluorescence in situ hybridization technology applied to phyto-
hemagglutinin-stimulated lymphocytes of 20 women with BCA and 10 control subjects. RESULTS: We showed that
both the HER2 and CEN17 loci in the stimulated BCA lymphocytes altered their characteristic pattern of synchronous
replication and exhibited asynchronicity. In addition, there was an increase in chromosome 17 aneuploidy. The fre-
quency of cells displaying asynchronous replication in the patients’ samples was significantly higher (P < 10−12
for HER2 and P < 10−6 for CEN17) than the corresponding values in the control samples. Similarly, aneuploidy in
patients’ cells was significantly higher (P < 10−9) than that in the controls. CONCLUSIONS: The HER2 and CEN17
aberrant replication differentiated clearly between BCA patients and control subjects. Thus, monitoring the replication
of these genes offers potential blood markers for the detection and monitoring of breast cancer.
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Introduction
A dominant aspect of the epigenetic profile of a DNA segment is the
timing of its synthesis during the S-phase of cell division [1–3]. Usually,
active loci replicate earlier than silent ones [1–4]. An archetypal exam-
ple of the close correlation between replication timing and epigenetic
activity, first recognized nearly 50 years ago, is the delayed replication
of the inactive X chromosomes in mammalian female cells when com-
pared with their active X counterparts [5,6]. A similar correlation is
seen in the allelic counterparts of monoallelically expressed genes,
which replicate asynchronously, whereas the allelic counterparts of bi-
allelically expressed genes replicate synchronously [7–9].
A simple method for evaluating the temporal order of allelic replica-
tion uses the fluorescent in situ hybridization (FISH) assay [10,11].
Using FISH, it has been demonstrated that the expressed counterpart
of a monoallelic gene usually replicates earlier than the inactive coun-
terpart [11–15]. Of major importance for this work is the fact that the
temporal order of replication of two allelic counterparts (either syn-
chronous or asynchronous) is preserved even in cells in which these
alleles are not expressed [16]. Therefore, the order of replication can
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be used as an epigenetic marker indicating whether a particular gene
is programmed to express biallelically or monoallelically [16–19].
Because replication markers are displayed even in tissues where the
gene itself is not expressed, researchers have been able to study repli-
cation patterns of a large repertoire of genes in peripheral blood lym-
phocytes after application (in vitro) of phytohemagglutinin (PHA),
a stimulator of T-lymphocyte division. Investigators have thereby es-
tablished the asynchronous allelic replication of various human mono-
allelically expressed genes, such as those subjected to X inactivation
[20,21], as well as numerous imprinted genes [12–15,22–24]. In ad-
dition, PHA-stimulated lymphocytes have revealed the synchronous
replication of various biallelically expressed genes involved in generat-
ing or limiting malignant growth (the so-called “cancer genes”), includ-
ing tumor suppressor genes TP53 and RB1 and oncogenes C-MYC
and HER2 [22–26].
Yet, in the peripheral blood lymphocytes of patients with hemato-
logical malignancies [26] or solid tumors—such as renal cell carcinoma
[22] or prostate cancer [23,24]—genes that normally replicate syn-
chronously (as exemplified by the above-noted “cancer genes”) lose
their synchronous mode and replicate asynchronously.
Moreover, certain chromosome-specific sequences (pericentromeric,
unexpressed DNA arrays), which normally display synchronous repli-
cation of their homologous counterparts, can also exhibit asynchronic-
ity in lymphocytes of patients with various types of cancer, including
ovarian [27], hematological [26], and prostate [23,24] malignan-
cies. The aberrant replication patterns of the pericentromeric arrays
seem to be associated with chromosomal malsegregation, which en-
genders increased levels of sporadic aneuploidy in the patients’ blood
cells [23,26,27].
Our present study aimed to determine whether replication markers
in peripheral blood lymphocytes can differentiate between breast cancer
patients (BCA) and healthy controls.
We show here that in PHA-stimulated lymphocytes of BCA patients,
theHER2 oncogene locus, assigned to the long arm of chromosome 17
(17q11.2-12) [28], fails to maintain its characteristic synchronous
mode of allelic replication and replicates asynchronously. In addition,
the pericentromeric array of chromosome 17 (CEN17 ), which nor-
mally exhibits a synchronous mode of allelic replication, reveals a loss
of synchrony accompanied by chromosome 17 aneuploidy.
Materials and Methods
Samples
Peripheral blood samples were obtained from 20 consenting women
diagnosed with breast cancer (BCA) and from 10 consenting cancer-
free control (CON) women. Nine of the 20 BCA patients donated
samples “at diagnosis” (before any therapeutic modality) and 11 donated
samples during the course of chemotherapy (“at treatment”). The 20BCA
patients ranged in age from 40 to 79 years, with a mean ± SD of 55 ±
12 years. The two subgroups of BCA patients did not differ significantly
in age (P > .70): the first, which donated at diagnosis, ranged from 29 to
79 years; and the second, which donated at treatment, ranged from 42 to
73 years (means ± SDs of 56 ± 15 and 54 ± 9 years, respectively). The ages
of CON subjects ranged from 20 to 66 years, with a mean ± SD of 43 ±
16 years. The age differences between the BCA and CON groups were
insignificant (P > .05).
Two of the 30 women in the study carried a mutated BRCA1 gene.
These mutation carriers belonged to the BCA group—one to the
patients analyzed “at diagnosis” and the other to the group sampled
“at treatment.”
Cultures
Each sample (0.2 ml of whole blood after heparinization) was trans-
ferred, for short-term culturing, into 5 ml of F10 medium supple-
mented with 20% fetal calf serum, 3% PHA, 0.2% heparin, and 1%
penicillin/streptomycin (Biologic Industries, Beit-Haemek, Israel).
Cultures were incubated at 37°C for 72 hours; colchicine (Sigma,
St Louis, MO) was added to a final concentration of 0.1 μg/ml for
1 hour, followed by hypotonic treatment (0.075 M KCl at 37°C for
15 minutes) and four washes, each with a fresh, cold (−20°C) 3:1
methanol-acetic acid solution. The cell suspensions were stored at
−20°C until use for FISH.
Probes
Two directly labeled commercial probes were used, each identify-
ing a specific region of chromosome 17: HER2 for 17q11.2-q12
(32-190001; Vysis, Chicago, IL) and the α-satellite probe specific for
centromere 17 (CEN17; 32-130017; Vysis). The oncogene HER2
probes is a member of the epidermal growth factor receptor or HER
(erb) gene family, whose amplification and/or overexpression are highly
associated with human breast cancer [28]. The CEN17 probe, usually
used for the enumeration of chromosome 17, identifies a specific non-
coding repetitive pericentromeric array, whose asynchronous replication
has been implicated in the appearance of aneuploidy [27].
Fluorescence In Situ Hybridization
Slide preparation, in situ hybridization, post washing, and detection
were all performed in accordance with the previously described pro-
tocol [23], with slight modifications. The two probes were diluted
to 1:100 (HER2) in catalog no. D003 or to 1:200 (CEN17) in catalog
no. D001 (Ingen’s DenHyb hybridization solutions; Insitus Biotechnol-
ogies, Albuquerque, NM). These replaced the hybridization solution
supplied with the probes. Five microliters of probe solution was placed
on the target area of the sample slides, which was covered with a 12-mm
round silanized coverslip (Insitus Biotechnologies) and sealed with rub-
ber cement. The slides were placed in a microheating system (True
Temp; Robbins Scientific, Sunnyvale, CA) at 76°C and denatured for
6 minutes at that temperature. The True Temp was turned off, and
the slides were allowed to hybridize overnight in the instrument.
Cytogenetic Evaluation
Slides were analyzed blindly using an Olympus BH2 fluorescent
microscope (Olympus, Hamburg, Germany) with a triple band-pass
filter (Chroma Technology, Brattleboro, VT). For replication analyses,
at least 100 cells exhibiting two distinct, well-defined fluorescence
signals were scored from each sample and for each tested probe. Signals
were divided into two categories: a single dot (singlet; S) representing a
nonreplicated DNA sequence and a double dot (doublet; D) indicating
a replicated sequence. Thus, cells exhibited patterns signaling synchro-
nicity (SS cells or DD cells; Figure 1, A–D) or those signaling asynchro-
nicity (SD cells; Figure 1, E and F ). Accordingly, a high frequency of
SD cells is indicative of asynchronous replication, whereas a low fre-
quency of SD points to synchronous replication [9]. Similarly, a high
frequency of SS cells reveals late replication of the locus in question, and
a high frequency of DD cells shows an early replication [8]. For each
sample and for each probe, the frequencies of SD, SS, and DD cells in
the total population of cells were recorded.
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For the determination of aneuploidy, at least 200 cells of each sample
prepared for the CEN17 replication studies were examined. Here, the
number of CEN17 fluorescent signals at interphase was recorded. Cells
containing one signal were designated as cells having monosomy 17,
cells with two signals were listed as normal, and cells with more than
two signals were recorded as multisomy 17. From the sum of mono-
somic and multisomic cells in the cell population, it was possible to
evaluate the frequency of aneuploidy.
Statistical Analysis
The statistical significance of differences between the two popula-
tions tested was carried out using the 2-tailed Student’s t test (Microsoft
Excel). P values .01 or less were considered statistically significant.
Ethical Basis
The study was approved by the Tel Aviv University Institutional
Helsinki Committee.
Results
Loss of Synchrony in Replication Timing of HER2 and CEN17
in PHA-Stimulated Lymphocytes of Breast Cancer Patients
The frequency of SD lymphocytes for the HER2 and CEN17 loci
was significantly higher in blood samples of the 20 women diagnosed
with BCA than of the 10 women without cancer (CON) (P < 10−12
forHER2 and P < 10−6 for CEN17 ). The mean ± SD values forHER2
ranged from 23% to 47% (34.6% ± 4.2%) in the BCA samples versus
7% to 17% (13.6% ± 3.3%) in the CON samples. For CEN17, the
values ranged from 21% to 31% (25.5% ± 3.2%) in the BCA samples
versus 6% to 19% (12.8% ± 3.9%) in the CON samples (Figures 2
and 3A).
Yet, the BCA blood lymphocytes obtained from patients at diagnosis
showed, for each locus, similar distributions of SD values to those from
patients analyzed during treatment (Figure 2). The corresponding SD
values of the two subgroups were comparable (P > .10 and P > .90 for
HER2 and CEN17, respectively).
It is worth mentioning that the lymphocytes of the two BRCA1
mutation carriers displayed SD values (33% and 34% for HER2 and
25% and 30% for CEN17 ), which were within the range observed in
the lymphocytes of the other BCA patients (Figure 2). Thus, the risk
factor associated with a BRCA1mutation seems to have no exacerbating
effect on the level of asynchronicity in the patients’ lymphocytes.
Regarding the HER2 and CEN17 loci, it should be noted that in
the CON group of patients, the two SD values were similar (P > .60;
Figure 3A). In this group, the two SS values (P > .60; Figure 3B) and the
two DD values (P > .90; Figure 3C ) were also similar, indicating that
both loci replicate at the same time, probably late, as judged from the
relative high SS values. However, in the BCA patients, the SD frequen-
cies displayed by HER2 were significantly higher (P < 10−8) than those
for CEN17. This was observed in nearly all the samples of this group
(Figures 2 and 3A). Interestingly, the high SD values obtained for
HER2 in the BCA patient lymphocytes were similar (P > .05) to those
we obtained for the SNRPN imprinted locus (ranging from 28% to
48%; 37.5% ± 5.4%) in a group of 25 blood samples taken from
cancer-free, healthy subjects ranging in age from 20 to 82 years (data
not shown). This indicates that in BCA patient lymphocytes, the SD
values ofHER2 reached a level observed normally for an imprinted gene.
Figure 1. Fluorescent signals in PHA-stimulated lymphocytes at in-
terphase after FISH with the CEN17 probe. (A and B) Cells with two
singlets (SS cells), in which neither allele has replicated. (C and D)
Cells with two doublets (DD cells), in which both alleles have repli-
cated. (E and F) Cells with one singlet and one doublet (SD cells),
which are S-phase cells in which one allele has replicated, whereas
its partner still has to do so.
Figure 2. Distribution of blood samples, according to their HER2
versus CEN17 SD values. BCA indicates breast cancer patients;
CON, control subjects. The arrows point to samples obtained form
BRCA1 mutation carriers. Note the clear separation between the
CON and the BCA samples.
670 Anomalies in Breast Cancer Patients’ Blood Cells Grinberg-Rashi et al. Neoplasia Vol. 12, No. 8, 2010
The increased SD cell frequency seen in the BCA samples for HER2
and CEN17was associated in both loci with a decrease in the frequency
of SS cells (Figure 3B) but not that of the DD cells (Figure 3C ). Ac-
cordingly, the SS cell values in the BCA samples were significantly lower
(P < 10−3 forHER2 and P = 10−3 for CEN17 ) and the DD values were
similar (P > .05 for HER2 and P > .90 for CEN17 ) to those in the
CON samples (Figure 3, B and C ). This finding points to a cancer-
dependent phenomenon that accelerates the replication timing of a
single allele from each studied locus but does not delay replication.
Aneuploidy for Chromosome 17 in PHA-Stimulated
Lymphocytes of BCA Patients
The asynchronous replication pattern of CEN17 in the BCA patient
lymphocytes was accompanied by increased aneuploidy of chromosome
17 (Figure 4A). The frequencies (%) of cells displaying aneuploidy,
namely, the monosomy (loss of one copy) or multisomy (gain of one
or more copies), of chromosome 17 were significantly higher (P < 10−9)
in the breast cancer patients than in the controls. The frequency of
cells with aneuploidy (sum of monosomy and multisomy) for chromo-
some 17 in the BCA samples ranged between 9.5% and 19.5%, with
a mean ± SD of 14.3% ± 3.2%, compared with a range of 5.0% to
8.5% (6.8% ± 1.1%) in the CON samples (Figures 4A and 5). The
increased level of aneuploidy in the BCA patients arises mostly from
monosomy and less frommultisomy (Figures 4B and 5). The frequency
of cells with monosomy for chromosome 17 in the BCA samples
ranged between 8.0% and 18.0% (11.9% ± 3.0%) versus between
4.5% and 7.5% (6.0% ± 1.3%) in the CON samples (Figure 4B).With
respect to the monosomy values, these groups differ significantly (P <
10−7; Figure 5A). Although much lower than the monosomy fre-
quencies, the multisomy level in the BCA samples (composed mainly
of trisomy 17) was significantly higher (P < 10−3) than that of the
CON samples (Figures 4B and 5).
As seen for the SD frequencies, the distribution of aneuploidy, mono-
somy, and multisomy values in the samples obtained from breast cancer
patients at diagnosis was comparable to those obtained from patients
under treatment (P > .70, P > .90, and P > .40, respectively; Figure 4).
Similarly, the BRCA1 mutation had no effect on the aneuploidy
levels of the BCA patients, as it had no effect on the SD levels, with
the percentage of aneuploidy, monosomy, and multisomy in the lym-
phocytes of the BRCA1mutation carriers having values similar to those
in the mutation-free cancer patients (Figure 4).
Discussion
We investigated the temporal order of allelic replication of HER2 and
a noncoding repetitive DNA sequence (CEN17 ) in breast cancer pa-
tients and controls. HER2 is an oncogene assigned to the long arm
of chromosome 17, whose amplification and/or overexpression in
breast cancers are associated with a poor outcome [28,29]. Yet,
HER2 is not expressed in lymphocytes of both control subjects and
BCA patients including those with HER2-amplified tumors [30].
CEN17 is the pericentromeric DNA array of chromosome 17 and, as
such, is under the control of complex epigenetic processes aimed to
ensure the fidelity of chromosome segregation and genomic stability
(reviewed in Gopalakrishnan et al. [31]). Both these loci in the periph-
eral blood lymphocytes of cancer-free women exhibit synchronous
allelic replication. Yet, in the peripheral blood lymphocytes of BCA
patients, they display a loss of synchrony and replicate asynchronously.
The level of asynchrony displayed by the HER2 locus reached the
levels of asynchrony normally observed for imprinted genes. These
results are in line with previous studies reporting that biallelically ex-
pressed genes in PHA-stimulated lymphocytes of patients with solid
tumors, such as renal cell carcinoma [22] or prostate cancer [23,24],
lose their normal mode of synchronous replication, which characterizes
biallelically expressed loci. Therefore, the loss of allelic synchronous
replication in lymphocytes can be defined as a non–tumor-specific
epigenetic malignant aberration. It is therefore reasonable that the
mechanisms giving rise to this aberration might be observed in various
other malignancies. Because the altered replication in the blood cells of
prostate cancer patients was linked to enhanced methylation capacity
[23,24], it is logical that the same holds true for the aberration in the
blood cells of the BCA patients. This is further enforced by the fact that
Figure 3. Mean values of (A) SD, (B) SS, and (C) DD for HER2 and CEN17. Values within the upper boxes of each frame present the level of
significance (P) of the differences between the control group (10 cases) and the breast cancer group (20 cases) for the designated locus.
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allelic counterparts that normally replicate asynchronously are usually
differentially methylated [7].
We show here that the aberrant replication displayed in lympho-
cytes of BCA patients at diagnosis, before any pharmaceutical treatment,
is similar to that observed in cells taken from the patients during chemo-
therapy. These results confirm a recent study showing that lymphocytes
of patients with hematological malignancies demonstrate replication
aberrations displayed at diagnosis, which are similar to those observed
after various substantial drug treatments. However, the aberrations are
eliminated after successful stem cell transplantation [32].
The appearance of identical replication aberrations in each of the
investigated loci of all BCA, prostate cancer [23,24], and renal cell
carcinoma [10] patients and in none of the cancer-free control sub-
jects may speak against an inherent predisposition theory [33,34]. In
our opinion, it seems to represent a phenomenon acquired later in life
that is linked to the malignant transition itself.
In this respect, it is worth mentioning that the two BCA patients
carrying the BRCA1 mutation displayed replication values similar to
those having nonmutated BRCA1 genes. This may suggest that BRCA1
malfunctioning is not related to the BCA replication aberrations de-
scribed here. Yet, two patients are not enough to conclude. Alterna-
tively, one could speculate that the epigenetic alteration, shown here
for the centromeric region of chromosome 17 and for the HER2 locus
assigned to 17q12, may span further along the long arm of chromo-
some 17. Such a development could disturb functional properties of
genes distal to HER2, namely BRCA1, which is located at 17q21 [35].
This seems plausible on the ground that epigenetic gene alteration in
cancer is not a localized event affecting discrete genes, but a generalized
condition that spans broad chromosomal regions [36], influencing the
entire genome and resulting in global epigenetic disequilibrium [37].
Interestingly, the loss of synchronous replication in the patients’ cells
was set off by the early replication of a single allele, inferred from the
decrease in the SS values but not in the DD values in the BCA patients’
cells. Because early replication is linked with functional genetic activ-
ity [1–6], it may correlate with the enhanced expression of oncogene
HER2. However, this is not the case here because HER2 expression
seems to be low in lymphocytes of BCA patients, regardless of its status
in tumors [30]. An advanced replication, not accompanied by elevated
levels of expression, may be explained by the fact that replication do-
mains can extend over large chromosomal regions containing many
genes that are not necessarily regulated by the replication timing con-
trol mechanisms (discussed in Woodfine et al. [3]). Thus, although
there is a general correlation between transcription and replication tim-
ing, the correlation between expression and replication timing often
does not hold at the level of a single gene. It is reasonable to suggest,
therefore, that the inherent epigenetic programming that coordinates
Figure 4. Distribution of blood samples according to their SD value
and aneuploidy frequencies for CEN17. (A) Aneuploidy frequency of
chromosome 17 versus SD value for CEN17. (B) Multisomic versus
monosomic frequencies of chromosome 17. The aneuploidy value
is the sum of the corresponding monosomic and multisomic values.
The arrows in each frame point to samples obtained form BRCA1
mutation carriers.
Figure 5.Mean and SD values of frequency of cells with aneuploidy
of chromosome 17. Values in the upper boxes present the level
of significance (P) of the differences between the control group
(10 cases) and the breast cancer group (20 cases) for the desig-
nated type of chromosomal aberration; the aneuploidy value is
the sum of the monosomic and multisomic corresponding values.
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allelic behavior turns loose (weaken) in blood lymphocytes of cancer
patients. This is in agreement with previous studies indicating that
the cancer-mediated abnormal asynchronous replication seems to be
a global non–locus-specific phenomenon, observed in blood lympho-
cytes of patients with ovarian cancer [27], leukemia. [26], renal cell
carcinoma [22], and prostate cancer [23,24]. Furthermore, the fact
that asynchronous replication is also displayed in nonexpressed cells
(well exemplified by the odorant genes, which are highly tissue-specific
but replicate asynchronously even in fibroblasts [16]) is also in accord
with our results.
Yet, the unscheduled replication of a single locus at the pericentro-
meric array may interfere with the overall chromosomal structure re-
quired for proper chromatid separation and/or segregation. Whatever
the mechanism, the two chromatid counterparts in the patients’ cells
probably separate earlier in mitosis than scheduled, as judged from
the far higher levels of monosomy than multisomy. Considering that
the mechanisms leading to aneuploidy in the lymphocytes of BCA
patients and prostate cancer patients are similar, we assume that the
aneuploidy exhibited for chromosome 17 in the BCA cells is non–
chromosome-specific and most probably affects other chromosomes
as well. We derive this from our observation that the lymphocytes of
prostate cancer patients showed increased aneuploidy levels, mostly
monosomy of each of five randomly examined chromosomes [23].
This reasoning is supported by findings showing that breast and pros-
tate cancer phenotypes, similar to those of other human cancers, display
high levels of aneuploidy, which arise from non–chromosome-specific
premature sister chromatid separations [38].
At the molecular level, loss of one copy of a chromosome is associ-
ated with a state of allelic imbalance, often giving rise to the loss of
heterozygosity, a phenomenon highly characteristic of the cancerous
phenotype. Loss of heterozygosity was first recognized for the RB1
(retinoblastoma) gene and later found in numerous other tumor sup-
pressor genes, including BRCA1 and TP53, both assigned to chromo-
some 17 (reviewed in Stanbridge [39]). Whatever the consequences of
chromosomal losses in the lymphocytes of patients with solid tumors,
these are accompanied by allelic replication timing aberrations, which
are non–tumor- and non–chromosome-specific.
Finally, the epigenetic aberrations detected in peripheral blood
cells of patients with solid tumors, being associated with the DNA
itself rather than its genetically activated products, offer promising
biomarkers for cancer detection and monitoring. If these epigenetic
changes disappear in breast cancer patients after complete cure from
malignancy (after successful surgical and/or chemotherapeutic treat-
ment), women could be provided with further proof and confidence
that they are cancer-free.
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